Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neose and BioGeneriX sign second protein deal
Under the agreement, BioGeneriX and Neose will enter into an initial three-month research period. Neose will receive a payment and supply of protein for research purposes. During the
Under the agreement, BioGeneriX and Neose will enter into an initial three-month research period. Neose will receive a payment and supply of protein for research purposes. During the
The court ruled in CAT’s favor on all counts, denying Abbott’s request for permission to appeal its judgment of 20 December 2004, although Abbott can now apply to
The abbreviated new drug application (ANDA) is for Levofloxacin tablets 750mg, the AB-rated generic equivalent of Ortho McNeil Pharmaceutical broad spectrum antibiotic. As the first ANDA applicant to
The randomized phase III clinical study of Tarceva (erlotinib) plus gemcitabine chemotherapy in patients with locally advanced or metastatic pancreatic cancer, met its primary endpoint by demonstrating a
The phase III study, named E3200, compared Avastin (bevacizumab) plus the FOLFOX4 chemotherapy regimen (oxaliplatin/5-FU/leucovorin), to FOLFOX4 alone in second-line metastatic colorectal cancer patients. Its primary endpoint, met
The company and the FDA agreed upon the phase I study protocol following an exchange of information and discussions centered on Tarvacin’s novel mechanism of action and the
Acyclovir 5% cream is marketed as an over-the-counter (OTC) product in these territories for the treatment of cold sores (herpes labialis). Under the terms of the agreement, Transport
Genecor develops and delivers innovative products and services into the healthcare, agri-processing, industrial and consumer markets. Danisco is to pay DKK 2,413 million ($419 million)in total for Genencor
The BMJ report alleged that Lilly failed to provide the FDA with documents relating to the risks associated with the antidepressant. The apology and retraction references the journal’s
Chiesi-developed CHF1512 (to be known in the future as GT1512) is a methyl-ester of levodopa (LDME), melevodopa, combined with the decarboxylase inhibitor carbidopa. The phase III clinical development